Evidence map›Paper›PMID 40027238›Full record

ArticleGenetics in medicine open2025

Reclassification of VUS in

Anna Benet-Pagès, Andreas Laner, Luis R Nassar, Tobias Wohlfrom, Verena Steinke-Lange, Maximilian Haeussler, Elke Holinski-Feder

Abstract read
In one paragraph

Article in Genetics in medicine open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Reclassification ofMedicina (Kaunas, Lithuania) · 2026
    Article
  4. Article
  5. Cancer genomic profiling predicts pathogenicity ofmedRxiv : the preprint server for health sciences · 2026
    Article
  6. Reclassification ofEuropean journal of breast health · 2025
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Anna Benet-PagèsMedical Genetics Center (MGZ), Munich, Germany.
Andreas LanerMedical Genetics Center (MGZ), Munich, Germany.
Luis R NassarGenomics Institute, University of California Santa Cruz, Santa Cruz, CA.
Tobias WohlfromMedical Genetics Center (MGZ), Munich, Germany.
Verena Steinke-LangeMedical Genetics Center (MGZ), Munich, Germany.
Maximilian HaeusslerGenomics Institute, University of California Santa Cruz, Santa Cruz, CA.
Elke Holinski-FederMedical Genetics Center (MGZ), Munich, Germany.

Funding

The UCSC Genome BrowserU41HG002371 · NHGRI · UNIVERSITY OF CALIFORNIA SANTA CRUZ · PI KENT, WILLIAM JAMES · 2012 to 2021
$36.6M
NHGRI NIH HHS U41 HG002371
6 · The paper itself

Abstract

Purpose: Variants of uncertain significance (VUS) are considered one of the most significant impediments to the translation of genetic test results into precise clinical recommendations. The 2015 American College of Medical Genetics and Genomics/Association for Molecular Pathology (ACMG/AMP) classification guidelines established a general framework for the assessment and classification of genetic variants; yet, gene-specific specifications are needed to enable better variant classification to reduce the number of VUS. The process of gene-specific adaptations of the ACMG/AMP codes is led and accompanied by ClinGen and implemented by Variant Curation Expert Panels (VCEP). The Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) VCEP recently published its specifications for the Methods: We reclassified 121 VUS identified in these genes with the latest annotation data using the standard ACMG/AMP classification system and recommendations from the Sequence Variant Interpretation and the ENIGMA specifications. To simplify the reevaluation process, we have created a University of California Santa Cruz Genome Browser track hub that displays the exact data points required for variant classification using the ENIGMA VCEP specifications at the exon and variant level (https://genome.ucsc.edu/s/abenet/BRCA.ENIGMA.hg19). Results: By comparing the codes used and their different weighting in the 2 approaches, we were able to demonstrate the superiority of the application of ENIGMA VCEP specifications, which resulted in a dramatic reduction of VUS (83.5% ENIGMA VCEP vs 20% ACMG/AMP + Sequence Variant Interpretation). Conclusion: For the diagnostic analysis of the

Indexed as

BRCA1BRCA2ENIGMAUCSC Genome BrowserVUS

Identifiers

PMID40027238
PMCPMC11869971

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.